Beta Bionics, Inc. (BBNX)
| Market Cap | 779.08M -34.9% |
| Revenue (ttm) | 127.27M +43.7% |
| Net Income | -83.12M |
| EPS | -1.85 |
| Shares Out | 54.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,376,417 |
| Open | 14.70 |
| Previous Close | 14.72 |
| Day's Range | 13.72 - 15.02 |
| 52-Week Range | 8.80 - 32.71 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 25.10 (+75.16%) |
| Earnings Date | Oct 27, 2026 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co... [Read more]
Financial Performance
In 2025, Beta Bionics's revenue was $100.25 million, an increase of 53.94% compared to the previous year's $65.12 million. Losses were -$73.20 million, 33.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BBNX stock is "Buy." The 12-month stock price target is $25.1, which is an increase of 75.16% from the latest price.
News
Senseonics and Beta Bionics Launch EversenseÂź 365 and iLetÂź Bionic Pancreas Integration
Eversense 365 now works with iLet, combining a year of accurate glucose monitoring with fully adaptive, automated insulin delivery to reduce the demands of managing diabetes
Beta Bionics Transcript: Stifel 2026 Healthcare Conference 2026
3D Intelligence was resubmitted after FDA questions on simulator validation; management sees H1 2027 as more likely, without delaying Mintâs Q1 launch. Mint capacity is planned to exceed 1.5 million annualized by end-2027, with automation and gradual margin gains central to the ramp.
Beta Bionics Transcript: 8th Annual Wolfe Research Healthcare Conference
Mint is expected to generate meaningful revenue in Q1 2027, with a minimum 1.5m disposables planned for 2027. Pharmacy coverage targets are 40% at launch and 50% by the end of its first market year; two new 3D algorithm modes have been resubmitted for FDA review.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of Beta Bionics, Inc. (NASDAQ: BBNX) securities that a securities class action has been filed on behalf of shareholders who acq...
Beta Bionics Announces Participation at Upcoming Investor Conferences
IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management w...
Kaplan Fox Reminds Investors of Beta Bionics, Inc. (BBNX) of the Deadline to Seek Lead Plaintiff Status on November 3, 2026
New York, New York--(Newsfile Corp. - November 2, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") ...
Kaplan Fox Encourages Beta Bionics, Inc. (BBNX) Investors With Significant Losses to Take Action Before the November 3, 2026 Lead Plaintiff Deadline
New York, New York--(Newsfile Corp. - October 30, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") ...
DEADLINE NEXT WEEK: Berger Montague Advises Beta Bionics, Inc. (BBNX) Investors to Contact the Firm Before November 3, 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - October 28, 2026) - Berger Montague PC, a leading national plaintiffs' law firm, announces a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX...
Beta Bionics price target raised to $21 from $18 at TD Cowen
TD Cowen raised the firmâs price target on Beta Bionics (BBNX) to $21 from $18 and keeps a Hold rating on the shares. The firm said Q3 was uneventful asâŠ
Beta Bionics price target raised to $24 from $20 at Piper Sandler
Piper Sandler analyst Matt OâBrien raised the firmâs price target on Beta Bionics (BBNX) to $24 from $20 and keeps an Overweight rating on the shares. The firm notes BetaâŠ
Beta Bionics price target raised to $22 from $20 at BofA
BofA raised the firmâs price target on Beta Bionics (BBNX) to $22 from $20 and keeps a Neutral rating on the shares as the firm adjusted estimates after earnings. PublishedâŠ
Beta Bionics Earnings Call Transcript: Q3 2026
Q3 sales hit a record $35.5 million, up ~30% YoY, while gross margin reached 57.3%. Mint is cleared for a Q1 2027 U.S. launch; FY2026 revenue guidance rose at the low end, and 3D Intelligence resubmission and manufacturing ramp remain key execution factors.
Beta Bionics Earnings release: Q3 2026
Beta Bionics released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Beta Bionics Slides: Q3 2026
Beta Bionics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
Beta Bionics Quarterly report: Q3 2026
Beta Bionics has published its Q3 2026 quarterly earnings report on October 27, 2026.
Beta Bionics reports Q3 EPS (52c), consensus (51c)
Reports Q3 revenue $35.51M, consensus $34.58M. The company said, âNew patient starts increased by a mid-single digit percentage versus the second quarter of 2026.â
Beta Bionics narrows FY26 revenue view to $124M-$126M from $121M-$126M
Consensus $124.36M. The company said, âRevenue guidance reflects a potential revenue deferral impact of up to $8.5 million in the fourth quarter of 2026 as new prospective iLet users couldâŠ
Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial resu...
What Does Beta Bionics, Inc.'s 37% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Beta Bionics, Inc. failed to disclose key facts to investors from July 30, 2025 through February 24, 2026; lead plaintiff deadline is November 3, 2026 BENSALEM TOWNSHIP, Pa., Oct. 27, 202...
What Should Beta Bionics, Inc. Investors Know After 37% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Beta Bionics, Inc. made misleading statements to investors from July 30, 2025 to February 24, 2026; lead plaintiff motions are due November 3, 2026 LOS ANGELES, Oct. 26, 2026 /PRNewswi...
Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Act Ahead of the Lead Plaintiff Deadline on November 3, 2026
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (âBeta Bionicsâ or the âCompanyâ) (NASDAQ: BBNX)...
BBNX Loss Notice: Beta Bionics Investors are Reminded of the November 3 Court Deadline â Contact BFA Law if You Lost Money
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and ce...
Kaplan Fox Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to the Lead Plaintiff Deadline on November 3, 2026
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (âBeta Bionicsâ or the âCompanyâ) (NASDAQ: BBNX)...
BBNX Deadline Reminder: Beta Bionics Investors are Notified to Contact BFA Law before the Expiration of the November 3 Lead Plaintiff Deadline
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and ce...
Kaplan Fox & Kilsheimer LLP Encourages Beta Bionics, Inc. (BBNX) Investors With Losses to Seek Appointment as Lead Plaintiff Before November 3, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") ...